📗 Cite This Artifact
ADAM12 Gene
ADAM12 Gene
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADAM12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ADAM12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ADAM metallopeptidase domain 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q26.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8030</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>602714</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000138744</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43827</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), Cancer, Muscular Dystrophy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">ADAM12 neutralizing antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">ADAM12 siRNA therapeutics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">ADAM12 promoter inhibitors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy vectors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Prodomain</td>
<td>Enzyme latency, secretion</td>
</tr>
<tr>
<td class="label">Metalloprotease</td>
<td>Substrate cleavage</td>
</tr>
<tr>
<td class="label">Disint
ADAM12 Gene
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADAM12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ADAM12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ADAM metallopeptidase domain 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q26.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8030</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>602714</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000138744</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43827</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), Cancer, Muscular Dystrophy</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">ADAM12 neutralizing antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">ADAM12 siRNA therapeutics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">ADAM12 promoter inhibitors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy vectors</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Prodomain</td>
<td>Enzyme latency, secretion</td>
</tr>
<tr>
<td class="label">Metalloprotease</td>
<td>Substrate cleavage</td>
</tr>
<tr>
<td class="label">Disintegrin</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td class="label">Cysteine-rich</td>
<td>Protein interactions</td>
</tr>
<tr>
<td class="label">EGF-like</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">Transmembrane</td>
<td>Membrane anchoring</td>
</tr>
<tr>
<td class="label">Cytoplasmic tail</td>
<td>Signaling, localization</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Cleavage Site</td>
</tr>
<tr>
<td class="label">IGF-1 binding protein</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">TGF-α</td>
<td>Ala²⁴⁴-Val²⁴⁵</td>
</tr>
<tr>
<td class="label">IL-6R</td>
<td>Arg³⁵⁹-Ser³⁶⁰</td>
</tr>
<tr>
<td class="label">Notch</td>
<td>Val¹⁷¹⁴-Leu¹⁷¹⁵</td>
</tr>
<tr>
<td class="label">HB-EGF</td>
<td>Leu¹⁴⁴-Val¹⁴⁵</td>
</tr>
<tr>
<td class="label">Vitronectin</td>
<td>Multiple</td>
</tr>
</table>
ADAM12 (A Disintegrin And Metalloproteinase domain 12) is a metalloproteinase involved in cell adhesion, differentiation, and muscle development. It is located on chromosome 10q26.3 and has been studied in the context of [Alzheimer's disease](/diseases/alzheimers-disease), cancer, and muscular disorders.
Gene Information
Protein Structure
ADAM12 shares the typical ADAM domain architecture:
- Signal peptide: Directs protein to secretory pathway
- Prodomain: Maintains enzyme latency; removed for activation
- Metalloproteinase domain: Catalytic protease domain
- Disintegrin domain: Mediates cell adhesion
- Cysteine-rich region: Regulatory functions
- EGF-like domain: Protein interactions
- Transmembrane domain: Membrane anchoring
- Cytoplasmic tail: Signaling and localization
Molecular Function
ADAM12 participates in multiple cellular processes[@blobel2015][@kveiborg2006]:
Proteolytic Processing
- Cleaves growth factors (IGF-1, TGF-alpha)
- Processes cytokines and adhesion molecules
- Generates sheddases for membrane proteins
Cell Adhesion and Migration
- Mediates cell-cell interactions via integrin binding
- Facilitates epithelial-mesenchymal transition (EMT)
- Regulates cell matrix interactions
Signaling Pathways
- EGFR signaling: Releases EGF-like ligands
- IGF-1 signaling: Modulates growth factor availability
- Notch signaling: Participates in proteolytic cleavage
Expression Pattern
ADAM12 shows tissue-specific expression:
- High expression: Skeletal muscle, heart, placenta
- Moderate expression: Brain, lung, liver
- Low expression: Most other tissues
In the brain, ADAM12 is expressed in [neurons](/entities/neurons) and glial cells, with altered expression in neurodegenerative conditions.
Disease Associations
Alzheimer's Disease
ADAM12 may contribute to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through multiple mechanisms[@tousseyn2017]:
- APP processing: Potential involvement in [amyloid precursor protein](/entities/app-protein) cleavage
- Synaptic dysfunction: Effects on synaptic plasticity
- Neuronal survival: Role in anti-apoptotic signaling
Cancer
ADAM12 is frequently overexpressed in cancers:
- Breast cancer: Promotes tumor growth and invasion
- Pancreatic cancer: Associated with poor prognosis
- Glioma: Correlates with malignancy grade
Muscular Disorders
ADAM12 is involved in muscle development and regeneration:
- Duchenne muscular dystrophy: Elevated expression
- Muscle injury: Upregulated during regeneration
Therapeutic Potential
ADAM12 is being explored as a therapeutic target:
- Cancer therapy: Antibody-drug conjugates targeting ADAM12
- Muscle disorders: Modulating regeneration pathways
- Biomarker: Serum ADAM12 as cancer biomarker
ADAM12 in Alzheimer's Disease Pathogenesis
The Amyloid Precursor Protein Processing Pathway
The [amyloid precursor protein](/proteins/app-protein) (APP) is a transmembrane protein that undergoes proteolytic processing by three major secretases: alpha-, beta-, and gamma-secretases. ADAM12 has emerged as a significant non-canonical alpha-secretase with important implications for [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis[@tousseyn2017].
Alpha-Secretase Processing
ADAM12 processes APP within the amyloid-beta (Aβ) sequence, generating:
- sAPPα (soluble APP alpha): A neuroprotective fragment that promotes neuronal survival, synaptic plasticity, and memory formation
- CTFα (C-terminal fragment alpha): A membrane-retained fragment that can be further processed
This processing pathway is often termed the "non-amyloidogenic" pathway because it precludes formation of the Aβ peptide. ADAM12's activity therefore represents a potentially protective mechanism against amyloid deposition[@tousseyn2017].
Competition with Beta-Secretase
When ADAM12 activity is reduced:
- More APP is available for beta-secretase (BACE1) processing
- This leads to increased production of sAPPβ and CTFβ
- CTFβ is subsequently processed by gamma-secretase to generate Aβ peptides
- The shift toward amyloidogenic processing promotes plaque formation
Neuroprotective Effects of sAPPα
The sAPPα fragment generated by ADAM12 (and other alpha-secretases like ADAM9, ADAM10, and ADAM17) exerts multiple neuroprotective effects:
ADAM12 Expression in Alzheimer's Disease Brain
Studies have shown altered ADAM12 expression in AD brains:
- Elevated ADAM12 in AD brain: Some studies report increased ADAM12 mRNA and protein in AD temporal cortex and hippocampus
- Cellular localization: ADAM12 is expressed in neurons, astrocytes, and microglia, with highest expression in areas prone to amyloid deposition
- Correlation with pathology: ADAM12 expression correlates with both Aβ plaque burden and neurofibrillary tangle density in some brain regions
Temporal Pattern
ADAM12 expression changes appear to follow a temporal pattern in AD progression:
Mechanistic Links Between ADAM12 and AD Pathogenesis
Interaction with Presenilins
ADAM12 may interact with the gamma-secretase complex components (presenilin-1 and presenilin-2):
- ADAM12 cleavage products may influence gamma-secretase activity
- Competition between alpha- and gamma-secretase for substrate
- Potential feedback mechanisms affecting amyloidogenesis
Effects on Tau Phosphorylation
Beyond amyloid processing, ADAM12 may influence tau pathology:
- sAPPα generated by ADAM12 can modulate GSK-3β activity
- Reduced alpha-secretase activity may lead to increased tau phosphorylation
- ADAM12-mediated signaling affects multiple kinases involved in tau pathology
Neuroinflammation Modulation
ADAM12 plays a role in neuroinflammatory processes:
- Regulates cytokine release from microglia and astrocytes
- Influences blood-brain barrier permeability
- Modulates astrocyte reactivity in response to Aβ
ADAM12 in Parkinson's Disease
While less studied than in Alzheimer's disease, ADAM12 has emerging relevance to [Parkinson's disease](/diseases/parkinsons-disease):
Alpha-Synuclein Processing
ADAM12 may participate in processing of [alpha-synuclein](/proteins/alpha-synuclein) or related proteins:
- Potential cleavage of alpha-synuclein aggregates
- Modulation of protein aggregation pathways
- Effects on neuronal protein homeostasis
Dopaminergic Neuron Vulnerability
ADAM12 expression in dopaminergic neurons may influence their selective vulnerability:
- Modulates neurotrophic factor signaling
- Affects oxidative stress responses
- May influence mitochondrial function
Clinical Trials and Therapeutic Applications
ADAM12-Targeted Therapies
ADAM12 as Biomarker
Serum and urine ADAM12 levels have been investigated as biomarkers:
- Cancer diagnosis: Elevated ADAM12 in breast, ovarian, and pancreatic cancers
- Prognostic value: Higher levels correlate with poor prognosis in some cancers
- Monitoring: Potential for treatment response tracking
Research Directions and Knowledge Gaps
Key Unresolved Questions
Ongoing Research Areas
- Small molecule activators: Screening for compounds that enhance ADAM12 alpha-secretase activity
- Gene therapy approaches: AAV vectors expressing ADAM12 for neuroprotection
- Combination therapies: ADAM12 activation combined with other anti-amyloid strategies
- Biomarker development: Clinical validation of ADAM12 in cerebrospinal fluid
ADAM12 Structure-Function Relationships
Domain-Specific Roles
Post-Translational Modifications
ADAM12 undergoes several important post-translational modifications:
- Prodomain cleavage: Required for enzymatic activation
- glycosylation: Affects folding, stability, and secretion
- Phosphorylation: Modulates signaling functions
- Ubiquitination: Targets for degradation
Summary
ADAM12 is a multifunctional metalloproteinase with significant implications for neurodegenerative disease research. Its role as an alpha-secretase positions it as a potentially protective enzyme in Alzheimer's disease by promoting non-amyloidogenic APP processing. The resulting sAPPα fragment exerts neuroprotective effects on synaptic plasticity, neuronal survival, and neuroinflammation.
Understanding the regulation of ADAM12 expression and activity in the brain, and developing therapeutic strategies to modulate its function, represents a promising approach to neurodegenerative disease intervention.
Structural Biology of ADAM12
Crystal Structure Insights
The metalloproteinase domain of ADAM12 adopts the typical metzincin fold:
- Active site: HEXGHNLGxxHDED motif coordinates zinc ion
- S1 pocket: Determines substrate specificity
- Disintegrin loop: Mediates cell adhesion interactions
- Cysteine switch: Regulates prodomain removal
Substrate Specificity
ADAM12 cleaves numerous substrates beyond APP:
ADAM12 in Other Neurodegenerative Disorders
Huntington's Disease
Emerging evidence suggests ADAM12 involvement:
- Altered expression in HD brain
- Potential role in mutant huntingtin processing
- Effects on neurotrophic factor signaling
- Modulation of striatal neuron vulnerability
Multiple Sclerosis
ADAM12 may contribute to demyelination:
- Upregulated in demyelinating lesions
- Effects on oligodendrocyte function
- Blood-brain barrier disruption
- Inflammatory mediator release
Research Methodology
Detecting ADAM12 Activity
- Western blotting: Detect pro and active forms
- ELISA: Quantify sAPPα release
- Activity assays: Fluorogenic substrate cleavage
- Immunohistochemistry: Tissue localization
- qPCR: mRNA expression analysis
Key Publications
External Links
- [NCBI Gene: adam12](https://www.ncbi.nlm.nih.gov/gene/)
- [PubMed: adam12](https://pubmed.ncbi.nlm.nih.gov/?term=adam12+neurodegeneration)
Brain Atlas Resources
- [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data](/datasets/allen-human-brain-atlas)
- [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome](/datasets/brainspan-atlas)
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression
Mechanism Map
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-adam12 |
| kg_node_id | ADAM12 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-52499494793b |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-adam12'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-adam12?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[ADAM12 Gene](http://scidex.ai/artifact/wiki-genes-adam12)
http://scidex.ai/artifact/wiki-genes-adam12